Search Results

Ono Pharma’s ONO-1110 failed five Phase 2 trials, leading to the discontinuation of development in depression and social anxiety. Work will continue for three pain indications.

• 71.2% 3-year overall survival for OST-HER2-treated patients vs. 45.8% comparable combined historical control (p = 0.002) • The two remaining patients who have not yet reached the 3-year timepoint from enrollment have trial monitoring visits scheduled for September 2026 and early October 2026 • Company receives $3.15 million in VAT refunds into OS Therapies UK, Ltd. subsidiary, with an additional $7.2 million in refundable VAT and R&D Tax Credits pending

Fiscal Q2 2027 net revenue of $29.1 million, Adjusted EBITDA* of $5.1 million, operating income of $2.4 million, and net income of $0.8 million - all quarterly records since fiscal Q4 2025, demonstrating significant year-over-year growth Product-level net revenue* from GRAFAPEX™ (treosulfan) for Injection of $5.7 million also a quarterly record Management to host conference call at 8:00 AM Eastern Time on Thursday, November 12, 2026

The TREM2 stabilizer failed to show efficacy in a Phase 2 trial of patients with early-stage ALS. This development follows two late-stage trial failures reported by Novartis last week, plus the news that the pharma has paused multiple CAR T cell trials following patient deaths.

Bristol Myers Squibb’s $2.3 billion Houston manufacturing campus is part of the company’s larger $40 billion investment designed to bolster American innovation and manufacturing.

ConV2X Releases Final Agenda Focused on AI, Clinical Development, FDA Regulation and Pharmaceutical Data Integrity

The investment will equip Bayer to make oncology, cardiovascular and renal care ingredients and drugs.